# Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer

> **NCT00639327** · PHASE2,PHASE3 · COMPLETED · sponsor: **Japan Clinical Cancer Research Organization** · enrollment: 300 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** S-1 + irinotecan
- **DRUG:** irinotecan

## Key facts

- **NCT ID:** NCT00639327
- **Lead sponsor:** Japan Clinical Cancer Research Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2011-04
- **Final completion:** 2011-06
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2011-06-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00639327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00639327, "Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00639327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*